RAF1 and hepatocellular carcinoma: Recent findings showed that sorafenib inhibited tumor growth through Raf-MEK-MAPK-independent pathways and STAT3 was a major kinase-independent target of sorafenib in HCC [22], and sorafenib inhibited growth and metastasis of HCC by blocking STAT3 [23].